Evidence map›Paper›PMID 36756447›Full record

ArticleRSC advances2023

Design, synthesis, anticancer and

Mohammad Navid Soltani Rad, Somayeh Behrouz, Saleh Aghajani, Marzieh Behrouz, Elham Zarenezhad, Ali Ghanbariasad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mohammad Navid Soltani RadMedicinal Chemistry Research Laboratory, Department of Chemistry, Shiraz University of Technology Shiraz 71555-313 Iran soltani@sutech.ac.ir behrouz@sutech.ac.ir +98 71 3735 4520 +98 71 3735 4500.ORCID https://orcid.org/0000-0002-6000-9053
Somayeh BehrouzMedicinal Chemistry Research Laboratory, Department of Chemistry, Shiraz University of Technology Shiraz 71555-313 Iran soltani@sutech.ac.ir behrouz@sutech.ac.ir +98 71 3735 4520 +98 71 3735 4500.
Saleh AghajaniMedicinal Chemistry Research Laboratory, Department of Chemistry, Shiraz University of Technology Shiraz 71555-313 Iran soltani@sutech.ac.ir behrouz@sutech.ac.ir +98 71 3735 4520 +98 71 3735 4500.
Marzieh BehrouzMedicinal Chemistry Research Laboratory, Department of Chemistry, Shiraz University of Technology Shiraz 71555-313 Iran soltani@sutech.ac.ir behrouz@sutech.ac.ir +98 71 3735 4520 +98 71 3735 4500.
Elham ZarenezhadNon-communicable Diseases Research Center, Fasa University of Medical Sciences Fasa Iran.ORCID https://orcid.org/0000-0003-2805-1910
Ali GhanbariasadDepartment of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences Fasa Iran.
Shiraz University of Technology · IRFasa University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this research the synthesis, characterization, anticancer and the cytotoxicity assessments of novel 8-caffeinyl-triazolylmethoxy hybrid conjugates have been described. These compounds are the first caffeine-1,2,3-triazolyl hybrid molecules that structurally are composed of three compartments comprising caffeinyl, 1,2,3-triazolyl and

Identifiers

PMID36756447
PMCPMC9850771
OpenAlexW4317435435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.